Cargando…

Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data

The strength of the immune response, as measured by antibody concentrations, varies between pneumococcal conjugate vaccines (PCVs). Linking immunogenicity and effectiveness is necessary to assess whether changes in immune response from currently recommended PCVs to next-generation vaccines could imp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ryman, Josiah, Weaver, Jessica, Hu, Tianyan, Weinberger, Daniel M., Yee, Ka Lai, Sachs, Jeffrey R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640717/ https://www.ncbi.nlm.nih.gov/pubmed/36344529 http://dx.doi.org/10.1038/s41541-022-00538-1

Ejemplares similares

Cost-Effectiveness Analysis of Routine Use of 15-Valent Pneumococcal Conjugate Vaccine in the US Pediatric Population
por: Huang, Min, et al.
Publicado: (2023)

Maintenance of an Immunogenic Response to Pneumococcal Vaccination in Children With Sickle Cell Disease
por: Rahim, Mahvish Q., et al.
Publicado: (2022)

1480. Incidence of Non-Invasive Pneumococcal Pneumonia in Children in the United States before and after Introduction Pneumococcal Conjugate Vaccines (PCV7 and PCV13) during 1998-2018
por: Hu, Tianyan, et al.
Publicado: (2020)

2711. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Older Adults
por: Lewis, Ned, et al.
Publicado: (2019)

Effectiveness of 13-pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease in children in the Dominican Republic
por: Tomczyk, Sara, et al.
Publicado: (2018)

Economic burden of acute otitis media, pneumonia, and invasive pneumococcal disease in children in the United States after the introduction of 13-valent pneumococcal conjugate vaccines during 2014–2018
por: Hu, Tianyan, et al.
Publicado: (2023)

Serologic response to pneumococcal vaccination in children experiencing recurrent invasive pneumococcal disease
por: Ingels, Helene A. S., et al.
Publicado: (2018)

Immunogenicity and Efficacy of Pneumococcal Conjugate Vaccine (Prevenar13(®)) in Preventing Acquisition of Carriage of Pneumococcal Vaccine Serotypes in Tanzanian Children With HIV/AIDS
por: Makenga, Geofrey, et al.
Publicado: (2021)

Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998–2018
por: Hu, Tianyan, et al.
Publicado: (2022)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination
por: Bhorat, As’ad E., et al.
Publicado: (2015)

Healthcare resource utilization and cost of pneumococcal disease in children in Germany, 2014–2019: a retrospective cohort study
por: Hu, Tianyan, et al.
Publicado: (2023)

Pneumococcal infections in children with sickle cell disease before and after pneumococcal conjugate vaccines
por: Adamkiewicz, Thomas V., et al.
Publicado: (2023)

Comparison of the Impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal Conjugate Vaccine 13 on Invasive Pneumococcal Disease in Equivalent Populations
por: Naucler, Pontus, et al.
Publicado: (2017)

Invasive Pneumococcal Disease after Routine Pneumococcal Conjugate Vaccination in Children, England and Wales
por: Ladhani, Shamez N., et al.
Publicado: (2013)

Filling evidence gaps on the impact of pneumococcal vaccines
por: Weinberger, Daniel M
Publicado: (2017)

Pneumococcal conjugate vaccination schedules in infants—acquisition, immunogenicity, and pneumococcal conjugate and yellow fever vaccine co-administration study
por: Mackenzie, Grant A., et al.
Publicado: (2022)

Effectiveness of pneumococcal conjugate vaccines against invasive pneumococcal disease among children under five years of age in Africa: A systematic review
por: Ngocho, James Samwel, et al.
Publicado: (2019)

Effectiveness of 7-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Medically At-Risk Children in Australia: A Record Linkage Study
por: Kabir, Alamgir, et al.
Publicado: (2022)

Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals
por: Nunes, Marta C., et al.
Publicado: (2012)

Systematic Review of the Effect of Pneumococcal Conjugate Vaccine Dosing Schedules on Immunogenicity
por: Deloria Knoll, Maria, et al.
Publicado: (2014)

Pneumococcal Surface Proteins as Virulence Factors, Immunogens, and Conserved Vaccine Targets
por: Aceil, Javid, et al.
Publicado: (2022)

Burden of invasive pneumococcal disease in children in Casablanca, Morocco four years after the introduction of pneumococcal vaccination
por: Chikhaoui, Amar, et al.
Publicado: (2022)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
por: Shiramoto, Masanari, et al.
Publicado: (2015)

Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older
por: Vila-Corcoles, Angel, et al.
Publicado: (2010)

Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013–2017
por: Shimbashi, Reiko, et al.
Publicado: (2020)

151. Evaluation of Pneumococcal Vaccine Effectiveness Against Invasive Pneumococcal Disease Among US Medicare Beneficiaries ≥65 Years Old
por: Pilishvili, Tamara, et al.
Publicado: (2018)

Association Between the Decline in Pneumococcal Disease in Unimmunized Adults and Vaccine-Derived Protection Against Colonization in Toddlers and Preschool-Aged Children
por: Weinberger, Daniel M, et al.
Publicado: (2019)

Missed Pneumococcal Vaccination Opportunities in Adults With Invasive Pneumococcal Disease in a Community Health System
por: Schulz, Paul S, et al.
Publicado: (2022)

Incidence of non-invasive all-cause pneumonia in children in the United States before and after the introduction of pneumococcal conjugate vaccines: a retrospective claims database analysis
por: Hu, Tianyan, et al.
Publicado: (2023)

Invasive Pneumococcal Disease and 7-Valent Pneumococcal Conjugate Vaccine, the Netherlands
por: van Deursen, Anna M.M., et al.
Publicado: (2012)

Systematic Review of the Effect of Pneumococcal Conjugate Vaccine Dosing Schedules on Vaccine-type Invasive Pneumococcal Disease Among Young Children
por: Conklin, Laura, et al.
Publicado: (2014)

Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany
por: van der Linden, Mark, et al.
Publicado: (2016)

Effectiveness of pneumococcal conjugate vaccination against invasive pneumococcal disease among children with and those without HIV infection: a systematic review and meta-analysis
por: Vardanjani, Hossein Molavi, et al.
Publicado: (2019)

Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease
por: Melegaro, Alessia, et al.
Publicado: (2010)

Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccination
por: van den Biggelaar, Anita H. J., et al.
Publicado: (2017)

Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany
por: van der Linden, Mark, et al.
Publicado: (2015)

2555. Predicting Risk of Breakthrough Invasive Pneumococcal Disease in Children After 13-Valent Pneumococcal Conjugate Vaccination
por: Yildirim, Melike, et al.
Publicado: (2018)

A reflection on invasive pneumococcal disease and pneumococcal conjugate vaccination coverage in children in Southern Europe (2009–2016)
por: Moreira, Marta, et al.
Publicado: (2016)

Impact of pneumococcal conjugate vaccine on invasive pneumococcal disease in children under 5 years of age in the Czech Republic
por: Kozakova, Jana, et al.
Publicado: (2021)

A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV
por: Wilck, Marissa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_41k934mu6enbmtv5hknt0c6qgv